The convenience gap is closing. Amgen competitors noticed.
Amgen fixed the one thing keeping competitors in the race: a subcutaneous version of its blockbuster thyroid eye disease drug Tepezza. But the window it bought may be shorter than it looks.
image from Gemini Imagen 4
Amgen reported positive Phase 3 results for a subcutaneous formulation of Tepezza, showing 76.7% proptosis response at week 24 (p<0.0001) versus 19.6% for placebo, delivered via an automated on-body injector with no new safety signals. This directly addresses the competitive vulnerability created by the existing IV version's requirement for hours-long infusion center visits, which smaller competitors like Viridian Therapeutics (BLA already submitted for veligrotug) and Sling Therapeutics (oral IGF-1R inhibitor in Phase 2b/3) were targeting. The data supports Amgen's $27.8 billion Horizon Therapeutics acquisition thesis, with FDA approval timing now the critical variable determining whether the convenience gap is closed or merely narrowed.
- •Subcutaneous Tepezza's 76.7% proptosis response rate appears comparable to historical IV data, suggesting the formulation switch preserved clinical efficacy without new safety signals over 24 weeks
- •Viridian's veligrotug BLA is already under FDA review, creating a narrow window for Amgen to establish the subcutaneous version as the standard before competitive entry
- •Competitors lacked head-to-head trials, but the subcutaneous delivery mechanism directly neutralizes their core value proposition of at-home convenience
